SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: PFIZER INC
Filing Type: Form 13F Information Table (Statement of Holdings)
Reporting Period: The filing text does not explicitly state the quarter end date in the narrative, though the metadata indicates a period of 2026 Jun 30. The table lists holdings as of the reporting date.
Context: This filing discloses Pfizer Inc.'s equity holdings in other public companies. It is a regulatory requirement for institutional investment managers to report their long positions in U.S. equities.
Key Financial Metrics and Holdings
The filing details specific equity positions rather than Pfizer's own financial performance (revenue, profit, cash flow). The following table summarizes the reported holdings by issuer:
| Issuer Name | Security Class | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|---|
| Allogene Therapeutics Inc | Common Stock | 22,032,040 | $46,928,245 | Sole |
| Pyxis Oncology Inc | Common Stock | 5,952,263 | $16,487,769 | Sole |
| Arvinas Inc | Common Stock | 3,457,815 | $27,662,520 | Sole |
| Caribou Biosciences Inc | Common Stock | 4,690,431 | $7,879,924 | Sole |
| Cardiff Oncology Inc | Common Stock | 2,411,575 | $3,014,469 | Sole |
| Spero Therapeutics Inc | Common Stock | 2,362,348 | $5,338,906 | Sole |
| Wave Life Sciences Ltd | Shares | 1,875,000 | $10,931,250 | Discretionary |
| Agomab Therapeutics NV | ADS | 75,000 | $1,035,750 | Sole |
| Biohaven Ltd | Common Stock | 505,645 | $8,004,360 | Sole |
| Zentalis Pharmaceuticals Inc | Common Stock | 953,834 | $3,853,489 | Sole |
| Zura Bio Ltd | Class A Ordinary Shares | 538,841 | $2,882,799 | Sole |
| Oric Pharmaceuticals Inc | Common Stock | 372,904 | $3,553,775 | Sole |
| Celcuity Inc | Common Stock | 295,652 | $29,550,417 | Sole |
| Ginkgo Bioworks Holdings Inc | Class A Common | 2,928 | $30,012 | Mixed (Sole/Discretionary) |
| NextCure Inc | Common Stock | 44,347 | $72,967 | Mixed (Sole/Discretionary) |
| Bolt Biotherapeutics Inc | Common Stock | 31,305 | $133,832 | Discretionary |
| Senseonics Holdings Inc | Common Stock | 2,171 | $12,418 | Discretionary |
Note: Some issuers have multiple entries representing different voting authority types (Sole vs. Discretionary). Values are aggregated where applicable for clarity.
Material Changes and Observations
The filing text does not provide comparative data against the prior quarter; therefore, material changes in position size or value cannot be calculated from this document alone. The portfolio is heavily concentrated in the biotechnology and pharmaceutical sectors, with significant positions in Allogene Therapeutics, Arvinas, and Pyxis Oncology.
Guidance, Risks, and Contingencies
Guidance/Outlook: Not applicable. Form 13F is a historical snapshot of holdings and does not contain forward-looking guidance or management commentary.
Risks: The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness. The concentration in early-stage biotech firms implies high volatility and regulatory risk for the underlying portfolio.
Key Facts for Investor Verification
- Portfolio Composition: Verify if the heavy weighting in biotech/biopharma aligns with Pfizer's stated investment strategy or if these are strategic minority stakes.
- Valuation Accuracy: Confirm the share prices used to calculate the "Value" column, as biotech stocks can be highly volatile.
- Voting Rights: Note the distinction between "Sole" and "Discretionary" voting authority, which may indicate different levels of control or management over specific positions.
- Reporting Date: Cross-reference the metadata date (2026 Jun 30) with the actual filing date to ensure the data reflects the correct quarter.